Figure 5
Combined inhibition of AKT/mTOR and AURKA signaling reduces tumor burden in a mouse xenograft model of RCC. (A) Schematic showing study design using a 786-0 mouse xenograft model treated with vehicle, and MLN8237. (B) Line chart plotted to show tumor volume (Week 1–Week 6). Vehicle (black circles), MLN8237 (red squares). (C) Scatter plot depicting the final tumor volume (mm3) from mice treated as indicated. *Statistical significance (Kolmogorov–Smirnov test) with p-value as indicated. (D) Schematic showing study design using a 786-0 mouse xenograft model treated with Vehicle, MLN8237, NVP-BEZ235 or a combination of MLN8237 and NVP-BEZ235. (E) Line chart plotted to show tumor volume (Week 1–Week 5, Week 4 the tumors were not measured and therefore not plotted). Vehicle (black circles), MLN8237 (blue squares), NVP-BEZ235 (BEZ235) (green triangle) and a combination of MLN8237 and NVP-BEZ235 (red line). (F, G) Scatter plot depicting the final tumor volume (mm3) (F) and final tumor weight (g) (G) from mice treated as indicated. *Statistical significance (Kolmogorov–Smirnov test) with p-values as indicated. (H, I) Representative images showing staining from tumor tissue for each of the treatments using Ki67 (H) and H&E (I) imaged at ×10 magnification. Scale bar, 500 μM.
